Eli Lilly's Mazdutide Shows Promise in Alcohol Use Disorder Study
Eli Lilly is conducting a proof-of-concept study to evaluate mazdutide in participants with alcohol use disorder.
Asset / Drug
Drug and asset intelligence for Mazdutide with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.